Straits Times Index
3,293.58 +5.83 (+0.18%) Nikkei
37,849.56 +221.08 (+0.59%) Hang Seng
17,556.67 +272.13 (+1.57%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,451.26 +208.95 (+0.33%) CMC Crypto 200
1,394.41 +11.84 (+0.86%)
DiaMedica Therapeutics Inc. (DMAC)
After hours:
| Previous close | 2.4500 |
| Open | 2.4900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4900 - 2.5500 |
| 52-week range | 1.5335 - 4.7500 |
| Volume | |
| Avg. volume | 39,716 |
| Market cap | 96.034M |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
- Zacks
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Insider Monkey
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript March 20, 2024 DiaMedica Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2023 Conference Call. An […]
